SightStream Biotherapeutics
Walpole, US · Founded 2020 · Delaware corporation
Founders & leadership
DN
David NeafusExecutive
JW
Jason WernerinExecutive
RD
Reza DanaNamed on SEC filing
JZ
Jiagang ZhaoNamed on SEC filing
Board
SW
Samuel WuBoard director
WX
Wenkai XiangBoard director
Reported raises · per SEC filings
Form D private placements$5.1M disclosed across 3 of 4 rounds · 2022–2025
▶$1.8MraisedOct 2025 · 9 investors · BiotechnologyRule 506(b)
▶$1.8MraisedOct 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Samuel WuDirector
- Wenkai XiangDirector
- David NeafusExecutive Officer
- Reza DanaDirector
- Jason WernerExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedAug 2023 · 2 investors · BiotechnologyRule 506(b)
▶$250KraisedAug 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason WernerExecutive Officer, Director
- Jiagang ZhaoDirector
- David NeafusExecutive Officer
- Reza DanaDirector
- Offering amount
- $1.3M
- Amount sold
- $250K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3.1MraisedJun 2023 · 21 investors · BiotechnologyRule 506(b)
▶$3.1MraisedJun 2023 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jiagang ZhaoDirector
- Reza DanaDirector
- David NeafusExecutive Officer
- Jason WernerExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3.1M
- Proceeds to insiders
- $300K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2022 · 18 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJun 2022 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Reza DanaDirector
- David NeafusExecutive Officer
- Jason WernerExecutive Officer, Director
- Jiagang ZhaoDirector
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has SightStream Biotherapeutics raised?
- SightStream Biotherapeutics has disclosed $5.1M raised across 3 of its 4 known rounds.
- Where is SightStream Biotherapeutics headquartered?
- SightStream Biotherapeutics is headquartered in Walpole, US.